Stockscreener 앱 받기
3.73
6.98%
-0.28
시간 외 거래:
3.74
0.01
+0.27%
전일 마감가:
$4.01
열려 있는:
$3.96
하루 거래량:
69,291
Relative Volume:
0.52
시가총액:
$211.75M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-3.1083
EPS:
-1.2
순현금흐름:
$-58.82M
1주 성능:
-2.10%
1개월 성능:
-15.03%
6개월 성능:
-37.83%
1년 성능:
-5.33%
1일 변동 폭
$3.665
$3.96
1주일 범위
$3.665
$4.125
52주 변동 폭
$2.60
$7.77
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
3.73 | 216.29M | 0 | -66.86M | -58.82M | -1.20 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
40,289 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BNP Paribas Financial Markets - Defense World
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - The Globe and Mail
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
As Gold Pushes Higher, Junior Miners Begin to Show Signs of Life - The Globe and Mail
Palantir vs. IBM: The Breakthrough Wall Street Is Missing - The Globe and Mail
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Northern Trust Corp Purchases 51,351 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
3 Penny Stocks With Market Caps As Low As $70M To Watch - Yahoo Finance
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox - Genetic Engineering and Biotechnology News
Promontory Therapeutics Announces Successful End of Phase 2 Meeting with US FDA on Phase 3 Registrational Study Design for PT-112 in Patients with Metastatic Castration-Resistant Prostate Cancer - PR Newswire
Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LP - Defense World
Leerink Partnrs Analysts Lower Earnings Estimates for DSGN - The AM Reporter
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference - The Manila Times
Quantum Sandbox Act: Why These 3 Quantum Stocks Could Be Ready to Explode - The Globe and Mail
Q2 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World
Chardan Capital Issues Optimistic Forecast for CRSP Earnings - Defense World
FY2025 EPS Estimates for EYPT Decreased by Cantor Fitzgerald - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - The Globe and Mail
Ataxia Pipeline: Advancing Therapeutics and 32+ Leading - openPR.com
Barclays PLC Has $639,000 Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale - Morningstar
Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - marketscreener.com
Design Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results - The Manila Times
Design Therapeutics, Inc. SEC 10-Q Report - TradingView
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter ... - Bluefield Daily Telegraph
Invesco Ltd. Buys New Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
AI Proteins to Present Key Advances in Miniprotein Therapeutics Development at PEGS Boston 2025 - Business Wire
Friedreich's Ataxia Market Growth | Trends, Treatments & - openPR.com
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops - Yahoo Finance
Design Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated' - marketscreener.com
Design Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025 - Nasdaq
Design Therapeutics (DSGN) Reveals Positive Phase 1 Trial Results for DT-168 | DSGN Stock News - GuruFocus
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy - The Manila Times
JPMorgan Chase & Co. Buys 48,528 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
Geode Capital Management LLC Purchases 3,090 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Applying computational protein design to therapeutic antibody discoverycurrent state and perspectives - Frontiers
Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs - Business Wire
Biotech stocks jump as Makary outlines FDA vision, RBC comments - Baystreet.ca
Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025 - Nasdaq
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - The Manila Times
Design Therapeutics Phase 1 Data Shows Promise for Novel FECD Eye Drop Treatment | DSGN Stock News - Stock Titan
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics - Business Wire
Forget the Correction: 2 Artificial Intelligence Stocks That Are Still Worth Buying Anyway - The Globe and Mail
April 2025's Promising Penny Stocks - Yahoo Finance
Design Therapeutics names new Chief Medical Officer By Investing.com - Investing.com Canada
Design Therapeutics Names Chris Storgard as Chief Medical Officer - marketscreener.com
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):